Data from animal and in vitro studies suggest that the growth-promoting eff
ects of the adrenal androgen dehydroepiandrosterone sulfate (DHEAS) may be
mediated by stimulation of insulin-like growth factor-I (IGF-I) and/or inhi
bition of interleukin 6 (IL-6), a cytokine mediator of bone resorption. Thi
s study tests the hypotheses that there are effects of age on serum DHEAS,
IGF-I, and IL-6 levels, and that levels of IGF-I and IL-6 are related to DH
EAS levels. The study included 102 women: 27 premenopausal and 75 postmenop
ausal, including 35 postmenopausal women with osteoporosis, as defined by b
one mineral density scores by dual X-ray energy absorptiometry. DHEAS level
s decreased significantly with age (r = -0.52, P < 0.0001) and IGF-I levels
decreased significantly with age (r = -0.49, P < 0.0001). IL-6 levels incr
eased significantly with age (r = 0.36, P = 0.008). IGF-I was positively co
rrelated to DHEAS levels (r = 0.43, P < 0.0001, n = 102) and IL-6 levels we
re negatively correlated to DHEAS levels (r = -0.32, P = 0.021, n = 54). Le
vels of DHEAS and IGF-I were correlated with T scores of the spine and some
hip sites. In a multiple Variable model to predict DHEAS, age was an impor
tant predictor (P < 0.001), but osteoporosis status, IGF-I, and IL-6 were n
ot. The median DHEAS level was lower in the postmenopausal osteoporotic wom
en (67 mu g/dl, n = 35) than in the nonosteoporotic postmenopausal women (1
06.3 mu g/dl, n = 40, P = 0.03), but this was not significant after correct
ion for age. Age accounted for 32% of the variance in DHEAS levels. In summ
ary, DHEAS levels decreased with age and had a positive association with IG
F-I levels and a negative association with IL-6 levels. DHEA deficiency may
contribute to age-related bone loss through anabolic (IGF-I) and antiosteo
lytic (IL-6) mechanisms.